AbbVie vs Palantir

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 79)

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

Palantir

LeaderAI/ML Platforms

MLOps Platforms

Palantir (PLTR) reported $2.87B revenue in FY2024, up 29% YoY. US commercial revenue +54%. Market cap ~$250B. 3,800+ employees. Denver, CO. AIP (AI Platform) driving accelerating growth. S&P 500 member.

AI VisibilityBeta
Overall Score
B79
Category Rank
#1 of 1
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
84
Gemini
75

About

Palantir Technologies builds AI-powered software platforms for government agencies and commercial enterprises. Founded in 2003 by Peter Thiel and Alex Karp, the company initially focused on intelligence and defense applications before expanding to commercial markets.

Full profile

AI Visibility Head-to-Head

90
Overall Score
79
#9
Category Rank
#1
60
AI Consensus
71
stable
Trend
stable
99
ChatGPT
84
99
Perplexity
84
83
Gemini
75
96
Claude
74
95
Grok
81

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.